Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.
Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
Company Research
Source: GlobeNewswire
- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development- SAN DIEGO and SUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biotech company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the appointment of David Gandara, M.D., to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Gandara, Professor Emeritus and Senior Advisor of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), brings deep knowledge and understanding to the immuno-oncology field, and he is recognized for his translational research and clinical work in cancer drug and biomarker development. Dr. Gandara commented, "I am delighted to join Adagene’s SAB at such an exciting time in the company's evolution. Adagene’s i
Show less
Read more
Impact Snapshot
Event Time:
ADAG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAG alerts
High impacting Adagene Inc. - ADS, each representing 1.25 ordinary shares news events
Weekly update
A roundup of the hottest topics
ADAG
News
- Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target SolutionsPR Newswire
- Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board [Yahoo! Finance]Yahoo! Finance
- Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardGlobeNewswire
ADAG
Sec Filings
- 3/29/24 - Form 6-K
- 3/29/24 - Form 424B5
- 3/29/24 - Form 20-F
- ADAG's page on the SEC website